OLIGOMERIX Awarded National Institutes of Health (NIH) Grant to Develop Novel Drug Discovery Technology for Alzheimer’s Disease

NEW YORK--(BUSINESS WIRE)--OLIGOMERIX, Inc. today announced the receipt of a Small Business Innovation Research (SBIR) Phase I grant for $233,598 from the National Institute on Aging, National Institutes of Health (NIH), to develop high throughput technology for drug discovery for Alzheimer's disease. This technology targets Tau OLIGOMERS, small soluble aggregates of tau protein that contribute to the pathology of Alzheimer’s and other neurodegenerative diseases. Antibodies against Tau OLIGOMERS developed in this program will be used to select compounds inhibiting the accumulation of Tau OLIGOMERS for drug development and as biomarkers for drug efficacy during disease progression. The antibodies are being developed in collaboration with Dr. Michael Sierks (Arizona State University).